April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The package offers tools for exploring potential miRNA changes in female hair loss.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly medicines targeting harmful microbes, free for personal use.
The tool accurately measures hair count and size on scalps with 79.45% and 68.19% accuracy, respectively.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
The project developed and tested a method using plasma rich platelets to treat hair loss.
July 2023 in “Institutional Repositories DataBase (IRDB)” 14 citations
,
July 2021 in “Bioinformatics” rPanglaoDB helps study rare cell types by merging RNA data, showing fibrocytes aid in healing.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
106 citations
,
December 2015 in “Biomacromolecules” Keratin hydrogels can be customized for better tissue healing.
January 2026 in “Regenerative Biomaterials” Advanced hydrogels can autonomously deliver drugs to treat radiation skin injuries, but challenges remain for clinical use.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
1 citations
,
May 2017 in “Hair transplant forum international” PRP is beneficial for hair restoration.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly antimicrobials free for everyone.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
4 citations
,
March 2024 in “Journal of Investigative Dermatology” SPRY1 deficiency in skin cells causes stem cells to move to the skin surface, leading to increased pigmentation.
April 2017 in “bioRxiv (Cold Spring Harbor Laboratory)” The dfRootChip revealed how Arabidopsis roots adapt and grow in uneven conditions.
April 2019 in “Journal of Investigative Dermatology” The search scheme SMRI is faster and more secure for retrieving encrypted data from the cloud.
2 citations
,
May 2024 in “BMC Genomics” Certain genetic changes in the KRT82 gene may cause patchy skin in New Zealand rabbits.
February 2025 in “PubMed”
March 2014 in “Journal of clinical microbiology” Kerion, a scalp fungal infection, requires lab confirmation and is treated with antifungal medication and medicated shampoo.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
March 2026 in “Pediatric Dermatology” Generative AI tools can accurately score alopecia areata, reducing subjectivity in evaluations.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
6 citations
,
August 2016 in “Journal of Visualized Experiments” The CUBIC protocol allows detailed 3D visualization of proteins in mouse skin biopsies.
14 citations
,
March 2019 in “Plant methods” The new microrhizotron tool effectively observes and measures pepper plant roots non-destructively.
November 2022 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” Phosphatidylinositol 4-kinases are crucial for root growth, defense, and immunity in Arabidopsis thaliana.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.